[go: up one dir, main page]

NO20073250L - Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser. - Google Patents

Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.

Info

Publication number
NO20073250L
NO20073250L NO20073250A NO20073250A NO20073250L NO 20073250 L NO20073250 L NO 20073250L NO 20073250 A NO20073250 A NO 20073250A NO 20073250 A NO20073250 A NO 20073250A NO 20073250 L NO20073250 L NO 20073250L
Authority
NO
Norway
Prior art keywords
liver
dioxides
isothiazole
modulating compounds
aniline derivatives
Prior art date
Application number
NO20073250A
Other languages
English (en)
Inventor
Eva-Lotte Lindstedt Alstermark
Lanna Li
Patrik Holm
Pernilla Marie Sandberg
Kay Brickmann
Marianne Swanson
Anders Broo
Robert Judkins
Lars Weidolf
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073250L publication Critical patent/NO20073250L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

(I) Foreliggende oppfinnelse angår visse nye forbindelser med formel (I), fremgangsmåter for fremstilling av slike forbindelser, deres nytte for modulering av nukleære hormonreseptorer Lever X Reseptor (LXR) ? (NR1H3) og/eller ? (NR1H2) og for behandling og/eller forhindring av kliniske lidelser omfattende kardiovaskulære sykdommer så som aterosklerose; inflammatoriske sykdommer, Alzheimers sykdom, lipidlidelser (dyslipidemier) hvorvidt eller ikke forbundet med insulinresistens, type 2 diabetes og andre manifestasjoner av metabolsk syndrom, metoder for deres terapeutiske anvendelse og farmasøytiske preparater inneholdende dem.
NO20073250A 2005-01-10 2007-06-25 Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser. NO20073250L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500055A SE0500055D0 (sv) 2005-01-10 2005-01-10 Therapeutic agents 3
PCT/SE2006/000029 WO2006073366A1 (en) 2005-01-10 2006-01-09 Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20073250L true NO20073250L (no) 2007-07-19

Family

ID=34132528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073250A NO20073250L (no) 2005-01-10 2007-06-25 Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.

Country Status (19)

Country Link
US (2) US7723333B2 (no)
EP (1) EP1838687A4 (no)
JP (1) JP2008526844A (no)
KR (1) KR20070094964A (no)
CN (1) CN101137628A (no)
AU (1) AU2006204164B2 (no)
BR (1) BRPI0606391A2 (no)
CA (1) CA2594404A1 (no)
IL (1) IL184093A0 (no)
MX (1) MX2007008405A (no)
NO (1) NO20073250L (no)
NZ (1) NZ556214A (no)
RU (1) RU2415135C2 (no)
SA (1) SA06270201B1 (no)
SE (1) SE0500055D0 (no)
TW (1) TW200804318A (no)
UA (1) UA91992C2 (no)
WO (1) WO2006073366A1 (no)
ZA (1) ZA200705519B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070094963A (ko) * 2005-01-10 2007-09-27 아스트라제네카 아베 간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
US8476287B2 (en) * 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
BR112013005425A2 (pt) 2010-09-07 2018-05-02 Snu R&Db Foundation compostos sesterterpenos e suas utilizações
JP5681819B2 (ja) 2011-02-11 2015-03-11 バットマーク・リミテッド 吸入器コンポーネント
JP6320382B2 (ja) 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
IL300476B2 (en) 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
CN110105658B (zh) * 2019-04-04 2021-08-20 台州市黄岩聚丰机车有限公司 无卤阻燃聚丙烯电动自行车外饰件原材料
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428956A (en) * 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
IE53068B1 (en) * 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
US5411977A (en) * 1993-03-31 1995-05-02 The Dupont Merck Pharmaceutical Company Substituted 2,5-diaryl-4-isothiazolin-3-ones as antiinflammatory and antithrombotic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
WO1999051572A1 (en) 1998-04-03 1999-10-14 Sankyo Company, Limited Sulfonamide derivatives
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
JP2004500332A (ja) 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
WO2001019831A1 (en) * 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
JP2001163786A (ja) 1999-09-30 2001-06-19 Sankyo Co Ltd スルホンアミド誘導体を含有する酵素阻害剤
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
BR0110734A (pt) 2000-05-11 2003-02-04 Consejo Superior Investigacion Inibidores heterocìclicos de cinase de sintase de glicogênio gsk-3
YU46603A (sh) 2000-12-08 2006-05-25 Ortho-Mcneil Pharmaceutical Inc. Indazolil-supstituisana jedinjenja pirolina, kao inhibitori kinaze
CA2462862A1 (en) 2001-10-12 2003-04-17 Schering Corporation 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
GB0314302D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Novel compounds
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
KR20070094963A (ko) * 2005-01-10 2007-09-27 아스트라제네카 아베 간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
US20090029945A2 (en) * 2005-01-10 2009-01-29 Astrazeneca Ab Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4

Also Published As

Publication number Publication date
US7723333B2 (en) 2010-05-25
AU2006204164B2 (en) 2009-11-05
JP2008526844A (ja) 2008-07-24
UA91992C2 (ru) 2010-09-27
RU2007130151A (ru) 2009-02-20
US20100227847A1 (en) 2010-09-09
CA2594404A1 (en) 2006-07-13
SE0500055D0 (sv) 2005-01-10
ZA200705519B (en) 2008-08-27
KR20070094964A (ko) 2007-09-27
US20090005353A1 (en) 2009-01-01
CN101137628A (zh) 2008-03-05
RU2415135C2 (ru) 2011-03-27
EP1838687A4 (en) 2010-11-17
EP1838687A1 (en) 2007-10-03
BRPI0606391A2 (pt) 2009-11-17
WO2006073366A1 (en) 2006-07-13
US7960380B2 (en) 2011-06-14
MX2007008405A (es) 2007-09-21
NZ556214A (en) 2010-07-30
AU2006204164A1 (en) 2006-07-13
SA06270201B1 (ar) 2009-12-16
TW200804318A (en) 2008-01-16
IL184093A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
EP2963037B1 (en) Novel pyrazole derivative
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
US20130072496A1 (en) Formulations containing pyridazine compounds
TW200900058A (en) N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic application
NO20071703L (no) Kinazolinderivater
BR112012027640A2 (pt) composto, composição farmacêutica uso de um composto, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 e de tratamento ou prevenção de um distúrbio
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
NO20090328L (no) Nye forbindelser 385
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
EP4281054A1 (en) Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
TW201102373A (en) Methods of treating or preventing psoriasis, and/or Alzheimer's disease using indane acetic acid derivatives
AR038704A1 (es) Derivados de tiazol como antagonistas del receptor nyp
US20200270214A1 (en) NADPH Oxidase Inhibitors and Uses Thereof
NO20092400L (no) 4-(Heterocyclyl)Alkyl-N-(Arylsulfonyl) indole compounds and their use as 5-HT6 Ligands
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
SE0500056D0 (sv) Therapeutic agents 4
NO20090812L (no) Fenyl-prenyl-eter derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser
BR112018012934B1 (pt) Reguladores cftr e métodos de uso dos mesmos
SE0500058D0 (sv) Therapeutic agents 5

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application